Daily Archives: January 16, 2022
2022 Guidelines on the management of chronic venous disease of the lower limbs.
16 Jan, 2022 | 23:22h | UTC
RCT: Oral Vitamin D supplementation (60.000 IU per month) did not reduce mortality in patients 60 years or older (unscreened individuals in Australia, many without insufficiency, average 30ng/mL). Exploratory analyses pointed towards an increased risk of death from cancer.
16 Jan, 2022 | 23:13h | UTCThe D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
Related:
Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention
Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases
Research: Circulating vitamin D concentration and risk of seven cancers
Research: Vitamin D and risk of total and site specific cancers
Guidelines for the provision of nutrition support therapy in the adult critically ill patient.
16 Jan, 2022 | 23:19h | UTC
ERAS Guidelines for perioperative care in bariatric surgery.
16 Jan, 2022 | 23:21h | UTCRelated: Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Commentary on Twitter
#VisualAbstract ➡️ Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations: A 2021 Update@Jasosamd @iss_sic
??https://t.co/HknWwLUjCZ pic.twitter.com/amhszadwup— WJS (@WorldJSurg) January 5, 2022
Multi-Disciplinary Guideline: Management of nephrolithiasis in pregnancy.
16 Jan, 2022 | 23:17h | UTC
Commentary from the author on Twitter
https://t.co/bFtOYFgBmr Started as an assigned resident presentation. Turned into a set of multi-d guidelines implemented at the university level. Now published for all to reference! Thank you all authors for input & guidance @peepeeDoctor @willrobe1 @amy_krambeck @sapanambani
— Matthew Lee (@MSLee_MD) December 23, 2021
RCT: Vitamin D supplementation is not beneficial for the prevention of cardiovascular disease and cancer.
16 Jan, 2022 | 23:11h | UTCNews Release: Five years of high-dose vitamin D did not affect incidence of cardiovascular disease or cancer – University of Eastern Finland
Related:
Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention
Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases
Research: Circulating vitamin D concentration and risk of seven cancers
Research: Vitamin D and risk of total and site specific cancers
RCT: In patients undergoing emergency endotracheal intubation, 7-day survival was significantly lower with etomidate vs. ketamine (77.3% versus 85.1%), but 28 survival rates were not significantly different (etomidate 64.1% vs. ketamine 66.8%, p = 0.294).
16 Jan, 2022 | 23:09h | UTC
Commentary on Twitter
Etomidate vs ketamine for emergency endotracheal intubation, RCT
?801 critically ill pts assigned to receive etomidate (0.2–0.3 mg/kg) or ketamine (1–2 mg/kg)
?day 7 survival significantly lower with etomidate
?no significantly different day 28 survivalhttps://t.co/CkxufORC8A pic.twitter.com/xQ4AtCifc7— Intensive Care Medicine (@yourICM) December 17, 2021
Video: Is noninferior not inferior?
16 Jan, 2022 | 22:57h | UTCIs Noninferior Not Inferior? – NEJM Evidence
Commentary on Twitter
Stats, STAT! Watch this animated video that explores the basis for non-inferiority trials, the meaning of non-inferiority margins, and the interpretation of a non-inferiority trial’s results. #MedEd #ClinicalTrials https://t.co/wvDAHbQu8l pic.twitter.com/Z0LyJv1sN1
— NEJM Evidence (@NEJMEvidence) January 11, 2022
RCT: Ketamine induced remission in 46% of patients but was NOT non-inferior to electroconvulsive therapy for the treatment of hospitalized patients with unipolar depression.
16 Jan, 2022 | 23:01h | UTCNews Release: ECT more effective than ketamine in severe depression – Lund University
Commentary on Twitter
RCT-OL: 63% of inpatients with MDD receiving ECT remitted vs. 46% receiving ketamine infusions (p=0.026). Both ketamine and ECT required a median of 6 sessions to induce remission. Long-lasting AE include persisting amnesia with ECT https://t.co/tvJ0qwUu62 pic.twitter.com/NOQK8Xv8TW
— PfOL (@psychopharmacol) December 12, 2021
Perspective: Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit−risk ratio, not age.
16 Jan, 2022 | 22:53h | UTCCommentaries:
Researchers urge: ‘Prescribe aspirin based on benefit-to-risk not age’ – Florida Atlantic University
Preventive Aspirin Should Be Based on Benefit, Not Age – HealthDay
Cluster randomized trial: no added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis.
16 Jan, 2022 | 22:59h | UTC
Analysis: Sarcopenia: early prevention or overdiagnosis?
16 Jan, 2022 | 22:48h | UTCSarcopenia: early prevention or overdiagnosis? – The BMJ
Related: Overdiagnosis: it’s official – the term is now included in the medical subject headings (MeSH) vocabulary. (several articles on the subject)
Commentary from the author on Twitter
We have a new diagnosis! 2 billion people may turn into patients with sarcopenia. Despite no evidence to justify why we should diagnose elderly people. My latest article in @bmj_latest with @drjohnbrodersen and JBülow. #overdiagnosis #sarcopenia #EBM https://t.co/mNFxmuz4U1
— Christoffer Bjerre Haase (@BjerreHaase) January 13, 2022
Coming to consensus: the Delphi technique.
16 Jan, 2022 | 22:54h | UTCComing to consensus: the Delphi technique – European Journal of Cardiovascular Nursing
Viewpoint: Hierarchical payment models—a path for coordinating population- and episode-based payment models.
16 Jan, 2022 | 22:52h | UTCHierarchical Payment Models—A Path for Coordinating Population- and Episode-Based Payment Models – JAMA (free for a limited period)
Assessment and treatment of thyroid disorders in pregnancy and the postpartum period.
16 Jan, 2022 | 22:42h | UTCAssessment and treatment of thyroid disorders in pregnancy and the postpartum period – Nature Reviews Endocrinology (if the link is paywalled, try this one)
Commentary on Twitter
New content online: Assessment and treatment of thyroid disorders in pregnancy and the postpartum period https://t.co/KrXeocu8sd pic.twitter.com/HeSCXNkelb
— Nature Reviews Endocrinology (@NatureRevEndo) January 4, 2022
Review | Travelling with heart failure: risk assessment and practical recommendations.
16 Jan, 2022 | 22:46h | UTCTravelling with heart failure: risk assessment and practical recommendations – Nature Reviews Cardiology (if this link is paywalled, try this one)
Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge.
16 Jan, 2022 | 22:41h | UTCCommentary: Large international evaluation shows AI accurately diagnoses prostate cancer – Karolinska Institutet
Commentary from one of the authors on Twitter (thread – click for more)
Honored to be part of the recently published study in Nature Medicine on the global #AI competition PANDA as a member of the @Google team and an expert panel of 6 US and Canadian Uropathologists. Check out this thread for my 5 top takeaways ?#pathology #PathTwitter
— Dr. Mahul Amin (@DrMahul) January 14, 2022
Editorial: Towards evidence-based staffing: the promise and pitfalls of patient-to-intensivist ratios.
16 Jan, 2022 | 22:45h | UTCTowards evidence-based staffing: the promise and pitfalls of patient-to-intensivist ratios – Intensive Care Medicine (free for a limited period)
Related Study: Association of patient-to-intensivist ratio with hospital mortality in Australia and New Zealand – Intensive Care Medicine
Commentary on Twitter
Evidence-based staffing, beyond pt-to-intensivist ratio: understanding tipping point of when workload is too much & quality of critical care diminishes essential for #ICU organization, beyond #COVID19 crisis.
?Editorial https://t.co/63IrhL3MD6
?Refers to https://t.co/eZAzwu4EbI pic.twitter.com/QpAtj4fcqc— Intensive Care Medicine (@yourICM) January 13, 2022
U.S. Cancer statistics, 2022.
16 Jan, 2022 | 22:39h | UTCCancer statistics, 2022 – CA: A Cancer Journal for Clinicians
RCT: Nivolumab plus chemotherapy improved progression-free survival, but not overall survival, compared to placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer.
16 Jan, 2022 | 22:38h | UTCNivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)